4月2日，据CDE官网消息，映恩生物制药（苏州）有限公司联合申请药品“注射用DB-1310”，获得临床试验默示许可，受理号CXSB2500002。
公示信息显示，药品“注射用DB-1310”适应症：拟用于晚期/转移性实体瘤。
映恩生物制药（苏州）有限公司，成立于2020年，位于苏州市，是一家以从事医药制造业为主的企业。企业注册资本8000万美元，实缴资本7300万美元。
通过天眼查大数据分析，映恩生物制药（苏州）有限公司共对外投资了2家企业，参与招投标项目11次，知识产权方面有商标信息48条，专利信息20条，此外企业还拥有行政许可10个。
主要股东信息显示，映恩生物制药（苏州）有限公司由DUALITYBIO HK LIMITED持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.